Sucampo Pharmaceuticals — Q1 2014 Earnings Presentation
20 slides from Sucampo Pharmaceuticals's earnings presentation, May 7, 2014
Slide 1: First Quarter 2014 Results
First Quarter 2014 Results May 7, 2014 e @ SUCAMPO The Science of Innovation
Slide 2: Forward-Looking Statements
J Statements Silvia Taylor Senior Vice President, Investor Relations d Corp age e ? SUCAMPO 2 The Science of Innovation
Slide 3: Agenda
Agenda Introducti dE d-Looki Statements Silvia Taylor Highlights of the Quarter Peter Greenleaf (MTT EAe) eee & RESCULA® rf pdate mmercial U, Stanley G. Miele Pipeline and R&D Update Taryn Losch-Beridon Financial Performance Cary J. Claiborne Closing Remarks Peter Greenleaf $ sucaMPo 3 ‘The Science
Slide 4: Forward-Looking Statements
Forward-Looking Statements= product potential, future others, andlor regulatory actions. new information, 2014. $ sucaMPo 4 ‘The Science of Innovation
Slide 5: Peter Greenleaf
Peter Greenleaf Chief Executive Officer e @ SUCAMPO 5 The Science of Innovation
Slide 6: Areas of Emphasis
60 Day Areas of Emphasis ¢ Great PEOPLE ° Great SCIENCE ¢ Strong FUNDAMENTALS $ sucaMpo ‘The Science of Innovation
Slide 7: Q1 2014 Overview & Highlights
Q1 2014 Overview & Highlig Comprehensive Review of Our Strategy capital struct Operating structure, prostone technology platform, pipeline, partnerships, ure Plan to be shared in Q3 Strong Financial Performance « Reporting 31% YoY growth in revenues + Inthe U.S.: solid performance of AMITIZA In Japa
Slide 8: Stanley G. Miele
Stanley G. Miele President, Sucampo Pharma Americas, LLC and SVP, Sales and Marketing e @ SUCAMPO 8 The Science of Innovation
Slide 9: Continued AMITIZA YOY Growth
Continued AMITIZA YOY Growth + Net sales growth ‘owth of Rx growth of 3% for Qt" Market Growth Accelerating Strong Partner Class up 6% for Q1 2014 vs. Q1 2013 increasing patient- focused efforts Over 8M TRx’s in = 8 years?; heritage is driver of increased sal : i com ition; 91% Commercial Part D See
Slide 10: AMITIZA Global Snapshot
AMITIZA Global Snapshot- Japan va tt t be above our urand Abbot expectation « AMITIZAsales in Japan grew to $6.1M (+177%) « Abbott applying more than half of detailing efforts in Japan to AMITIZA * 2 week limitation removed ¢ Available market is over 21M patients, making Japan a a and growing driver
Slide 11: Taryn Losch-Beridon
Taryn Losch-Beridon Vice President, Clinical Development e ? SUCAMPO "1 The Science of Innovation
Slide 12: Clinical Focus
CLINICAL FOCUS LEAD COMPOUNDS PHASE 2 PHASE 3 COMPLETED MPROJECTED START BONGOING *Co-developing with R-Tech Ueno, Ltd SUCAMPO 12 ‘The Science of Innovation
Slide 13: Q1 2014 Performance
1014 Performance 4 Cary J. Claiborne Chief Financial Officer e ? SUCAMPO 13 The Science of Innovation
Slide 14: Strong Financial Performance
Strong Financial Performance it gor $0.02 $(0.08) $(3.1) Q1-13 Qi Q1-13 Q1-14 Net Income/(Loss) EPS $ sucampo 14 ‘The Science of Innovation
Slide 15: Q1 AMITIZA U.S. Net Sales
Qi AMITIZA U.S. Net Sales* ($ND= 75.0 $64.9 $ Q1-13 Q1-14 $ sucampo 15 “As reported by Takeda for royalty caleulation purposes ‘The Science of innovation
Slide 16: Total Revenues and Product Royalty Revenues
$22.2 Q1-13, Q1-14 Q1-13 Q1-14 Total Revenues* Product Royalty Revenues $sucampo = *® *Co-promotion, contract and collaboration revenue also are components of revenue. ‘The Science of innovation
Slide 17: Product Sales and R&D Revenues
Q1-13 Q1-14 Q1-13 Q1-14 Product Sales R&D Revenues Revenues $ sucampo 7 ‘The Science of Innovation
Slide 18: Results of Operations
fs-of Operations COGS: Increased volume of AMITIZA sales in an F's Dama) cas \clusion of clinical trial of our Rpeoret Ta eae tion, lower costs of our LSS trials and the 2013-t terminated collaboration with Numab AG, partially offset by increased spending with the first patients enrollment for the P
Slide 19: Financial Guidance
Financial Guidance Eull Year 2014 GAAP Net Income $3M -$5M GAAP EPS $0.06 - $0.11 $ sucaMPo ‘9 The Science of innovation
Slide 20: Peter Greenleaf
Peter Greenleaf Chief Executive Officer e @ SUCAMPO 20 The Science of Innovation
Sucampo Pharmaceuticals — Q1 2014 Earnings Presentation on 6ix